Allurion Technologies has launched AllurionMeds, a unique offering to patients that combines affordable and accessible weight loss medications with the company’s AI-native platform, featuring Coach Iris, to promote long-term weight maintenance, virtual access to dieticians and a connected smart scale measuring not just weight, but muscle and bone mass.
“Feedback from patients is clear; the weight must stay off. Our platform was designed specifically to help patients lose weight and keep it off,” said Dr Shantanu Gaur, Founder and Chief Executive Officer of Allurion. “AllurionMeds is built around safety, efficacy and, importantly, efficiency. Without affordable medications for weight loss and AI-powered behaviour change, we risk bankrupting the US healthcare system.”
The market opportunity for GLP-1s in the US continues to grow, with expectations that it exceeds US$100 billion with 30 million total users by 2030. Recent studies are reporting, however, that 30% of patients discontinue GLP-1 drugs in the first month with significant muscle mass loss. These issues, combined with prices in some instances exceeding US$1,300 per month, will further the obesity epidemic and lead to untenable expense in the US unless access and support is improved for the millions of Americans living with this disease.
The AllurionMeds GLP-1 program, with support from Coach Iris, will address the most common concerns from patients looking to begin a GLP-1 program. Patients in the program will receive access to the Allurion Connected Scale and Allurion’s GLP-1 companion app. The scale measures not only weight but also muscle and bone mass to ensure that both the quantity and quality of weight loss is being monitored. Previous studies have shown that Allurion’s scale, app and lifestyle modification program in conjunction with the Allurion Balloon have helped patients lose weight while actually gaining muscle mass and helped them keep the weight off in the long-run.
“We are taking our decade-long experience of treating over 150,000 patients to launch an innovative, AI-native platform designed to solve the problems GLP-1 users face and provide a best-in-class experience,” said Gaur. “Real-world use of GLP-1s has highlighted three critical issues: poor medication adherence and wrap-around support, muscle and bone mass loss, and untenable cost to the healthcare system. AllurionMeds leverages our existing platform to address all three of these issues by providing 24/7 AI-powered coaching, monitoring of weight, muscle mass and bone mass, and offering high quality and affordable compounded semaglutide delivered at home.”
AllurionMeds partnered with FDA-registered pharmacies to provide safe and financially accessible GLP-1 products available across the US. Together with Coach Iris, patients will receive GLP-1 drugs that are sourced from an FDA-registered 503b facility adherent to Current Good Manufacturing Practice (CGMP) regulations. Every batch has been tested for sterility and potency, among other things, before release.
“Safety and ease of use were paramount to us as we were designing AllurionMeds,” said Brian Conyer, Vice President of Digital Health at Allurion. “After careful evaluation of multiple partners, we selected pharmacies that met our high standards to create an experience that is ‘always on’ through Coach Iris. In the future, we intend to expand the types of GLP-1s available and also offer brand-name versions to provide patients with as many options as possible for their weight loss journey.”
Additionally, with the launch of AllurionMeds, the company has expanded its product offerings to all 50 states in the US. Previously, the company had launched the Virtual Care Suite, its B2B AI product, to obesity management clinics in the US.
“AllurionMeds further expands our presence in the United States,” added Gaur. “I believe the relationships we are creating with patients and providers in the US could benefit future product launches by creating a foothold in the largest obesity market in the world.”
Comments